The aim of this systematic review was to examine the efficacy of MDMA, ketamine, LSD, and psilocybin for the treatment of posttraumatic stress disorder (PTSD). A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text. Observational studies and RCTs which tested the efficacy of MDMA, ketamine, LSD, or psilocybin for reducing PTSD symptoms in adults, and reported changes to PTSD diagnosis or symptomatology, were included. Nine trials (five ketamine and four MDMA) met inclusion criteria. Trials were rated on a quality and bias checklist and GRADE was used to rank the evidence. The evidence for ketamine as a stand-alone treatment for comorbid PTSD and depression was ranked "very low", and the evidence for ketamine in combination with psychotherapy as a PTSD treatment was ranked "low". The evidence for MDMA in combination with psychotherapy as a PTSD treatment was ranked "moderate".
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/02791072.2020.1817639 | DOI Listing |
Prog Neuropsychopharmacol Biol Psychiatry
December 2024
Chiba University Center for Forensic Mental Health, Chiba 260-8670, Japan. Electronic address:
3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy) is a widely abused recreational drug that has also gained interest for potential clinical applications in mental health. With the growing recognition of gut microbiota's role in mental health, this study examined whether repeated oral MDMA administration could affect gut microbiota in the small intestine, cecum, and colon of male rats. Repeated oral MDMA administration (10 mg/kg/day for 14 days) caused significant changes in the gut microbiota across these regions, with distinct effects observed in each.
View Article and Find Full Text PDFDrug Test Anal
December 2024
Analytical Toxicology Laboratory, Analytical Toxicology Division, Health Sciences Authority, Singapore.
This study presents the development and validation of a drug testing method in hair, employing a semi-automated sample preparation procedure and gas chromatography-tandem mass spectrometry (GC-MS/MS) for simultaneous multidrug analysis in hair. The method aims to detect and quantify multiple drugs in hair, including amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, ketamine, norketamine, cocaine, benzoylecgonine, morphine, codeine and 6-monoacetylmorphine, using a comprehensive procedure involving decontamination, pulverization, clean-up using supported-liquid extraction (SLE) and a two-step derivatization process. The method validation included specificity, linearity, limit of detection (LOD), limit of quantification (LOQ), precision, accuracy, carryover, robustness and stability.
View Article and Find Full Text PDFLancet Psychiatry
January 2025
Champalimaud Research and Clinical Centre, Champalimaud Foundation, Lisbon, Portugal; Faculdade de Ciências Médicas, NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal. Electronic address:
Although studies of psychedelic-assisted psychotherapy are accumulating, there is no consensus regarding best practice of the psychotherapeutic component. In this systematic review, we summarised the quality of reporting on psychological interventions in research about psychedelic treatments. The design followed PRISMA guidelines and was preregistered in PROSPERO (CRD42022319221).
View Article and Find Full Text PDFJ Med Toxicol
December 2024
Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK.
Introduction: Novel Psychoactive Substance (NPS) use is increasingly prevalent and is often associated with severe acute recreational drug toxicity (ARDT). 258 UK deaths were attributed to NPS use in 2021. Confirmatory testing which identifies NPS is limited by expense and timeliness.
View Article and Find Full Text PDFAm J Psychiatry
December 2024
National Center for PTSD, U.S. Department of Veterans Affairs, Washington, DC (Sippel, Hamblen, Kelmendi, Schnurr, Holtzheimer); Geisel School of Medicine at Dartmouth, Department of Psychiatry, Hanover, NH (Sippel, Hamblen, Schnurr, Holtzheimer); Northeast Program Evaluation Center, U.S. Department of Veterans Affairs, (Sippel); Department of Psychiatry, Yale University School of Medicine, New Haven, CT (Kelmendi); Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, New York, NY (Alpert); Department of Psychiatry and Human Behavior, Butler Hospital, Brown University, Providence, RI (Carpenter); Department of Psychiatry, David Geffen School of Medicine, University of California, Los Angeles (Grzenda); Department of Psychiatry and Behavioral Health, The Ohio State University, Columbus (Kraguljac); Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA (McDonald); Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, and Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (Rodriguez); Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis (Widge); Dell Medical School, University of Texas at Austin, Austin (Nemeroff).
Posttraumatic stress disorder (PTSD) is a highly prevalent psychiatric disorder that can become chronic and debilitating when left untreated. The most commonly recommended first-line treatments for PTSD among adults are individual trauma-focused psychotherapies. Other evidence-based treatments include specific antidepressant medications and non-trauma-focused psychotherapies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!